Introduction {#Sec1}
============

Primary immunodeficiency (PID) comprises a large, heterogeneous group of disorders that result from defects in immune system development and/or function. Long considered as rare diseases, recent studies show that one in 2000--5000 children younger than 18 years is thought to have a PID. There are now around 350 single-gene inborn errors of immunity and the underlying phenotypes are as diverse as infection, malignancy, allergy, autoimmunity, and autoinflammation. Therefore, presenting features, severity, and age of diagnosis vary immensely. Hematopoietic cell transplantation (HCT) is a well-recognized curative therapy for many of these PIDs. Since the first transplant took place in 1968, utility of HCT was initially limited by high rates of graft failure and transplant-related morbidity and mortality; however, transplant survival and graft outcomes have significantly improved, particularly since 2000 \[[@CR1], [@CR2]\]. Many factors have contributed to this improvement including earlier diagnosis, a detailed graft selection hierarchy, superior HLA matching technology, improved methods for graft manipulation, greater availability of grafts, improved supportive care, vigilant infection surveillance and pre-emptive treatment, and more effective antimicrobial therapy. In the modern era, graft engineering, additional cellular therapy, and pharmacokinetic-guided conditioning regimens enable precise personalized transplant care including prescription of graft components, better cell-dosed grafts, and a patient-tailored conditioning regimen \[[@CR3], [@CR4]•, [@CR5]••\].

Short-term transplant survival outcomes must be carefully distinguished from long-term disease outcomes and late effects of transplant. As survival from transplant has improved, more attention is now given to long-term disease outcomes and quality of life. Therefore, the goal of conditioning is to give the least toxic regimen with minimal short- and long-term side effects but still achieve cure of the underlying condition. This review will focus on newer conditioning regimens, how they have changed, and possible future directions. It is important to note that success does not simply depend on which conditioning chemotherapeutic agents are employed but on a combination of factors such as additional serotherapy, timing and dosage, and stem cell source. In almost all cases, preparative conditioning with a combination of chemotherapeutic agents, with or without monoclonal antibodies, is required for successful engraftment and stable robust long-term immune reconstitution.

Definition {#Sec2}
==========

The intensity of the conditioning regimen can vary substantially and has been classified as myeloablative conditioning (MAC), reduced toxicity conditioning (RTC), reduced intensity conditioning (RIC), and minimal intensity conditioning (MIC) in decreasing order (Fig. [1](#Fig1){ref-type="fig"}). MAC, consisting of alkylating agents with or without total body irradiation (TBI), is expected to myeloablate the recipient's hematopoiesis which does not allow for autologous hematological recovery. This aims to prevent rejection by the use of supralethal chemotherapy to remove host-versus-graft reaction and create marrow niche space for donor stem cells. Newer myeloablative chemotherapy agents are being explored to reduce toxicity and enable safer HCT. These reduced toxicity conditioning (RTC) regimens, including pharmacokinetic targeted busulfan-fludarabine (Bu-Flu) and treosulfan-fludarabine, have a comparable myeloablative effect with conventional MAC but reduced organ toxicities. Compared to MAC, RIC has been traditionally characterized by reversible myelosuppression in the absence of stem cell rescue, reduced regimen-related toxicity, and a higher incidence of mixed chimerism. MIC is strictly non-myeloablative, does not eradicate host hematopoiesis, and allows relatively rapid autologous hematopoietic recovery without a transplant, but adequately myelosuppresses the recipient to enable at least partial donor engraftment.Fig. 1Intensity of conditioning regimen according to chemotherapy, pharmacokinetic guided dosing, timing of serotherapy, and combination of chemotherapy

Myeloablative Conditioning Regimens in PID {#Sec3}
==========================================

Historically, conditioning therapy prior to HCT in PID was based on the combination of alkylators busulfan and cyclophosphamide. However, many children with PID have significant comorbidities at the time of HCT, and these conventional myeloablative preparative regimens are associated with significant toxicity and a relatively high incidence of transplant mortality, as well as long-term sequelae. While initial results may have been acceptable, appreciation of acute conditioning toxicities and recognition of long-term sequelae mean that few centers now approach transplantation of PID patients with conventional myeloablative preparative regimens (Table [1](#Tab1){ref-type="table"}) \[[@CR6]--[@CR9]\].Table 1Outcome of HCT in PID after myeloablative conditioning regimensAuthor, YearYear of HCTNo. of patients/diagnosisMedian age at HCT (range), yearsDonor and stem cell sourceConditioning regimenOSFisher, 1994 \[[@CR6]\]1977--1991149 non-SCID PID received 171 transplantsRange 0.1--1665 MSD/MFD6 MUD78 MMUDBu+Cy12 additional TBIBefore 1985, 51.7%After 1985, 81.5%Klein, 1995 \[[@CR7]\]1981--199319 MHC class II deficiency (7 s HCT)1.4 (0.5--9.5)8 MFD marrow1 MMFD marrow10 HID marrowAll 7 s HCT used HID*MFD*Bu20mg/kg + Cy 200 mg/kg or Cy 50 mg/kg + ALG orCy 50 mg/kg + CCNU 300 mg/m^2^ + procarbazine 280 mg/kg + ALG*MMFD*Bu 16 mg/kg + Cy 200 mg/kg orBu 20 mg/kg + Cy 200 mg/kg + anti-LFA-1 antibody orBu 20 mg/kg + Cy 200 mg/kg + anti-LFA-1 antibody + anti-CD2 antibody47%Antoine, 2003 \[[@CR8]\]1968--19991082 HCT in 919 PID patients566 HCT in 475 SCID patients512 HCT in 444 non-SCID PID patientsSCID: 5.5 monthsNon-SCID: 34.6 months88% marrow12% PBSC0.7% CBT cell depletion:91% MD41% UD marrow205 SCID: unconditioned361 SCID: Bu 8 mg/kg + Cy 200 mg/kg512 non-SCID; Bu 16 mg/kg + cy 200 mg/kgSCID: 77% MD vs 54% in MMDNon-SCID: 71% MFD vs 42% MUD vs 59% MMDRenella, 2006 \[[@CR9]\]1981--200415 MHC class II deficiency1.5 (0.3--5.4)13 MFD marrow2 MUD marrowBu 16-20 mg/kg + Cy 200 mg/kg + ATG in MUD53%*ALG* antilymphocyte globulin, *Bu* busulfan, *CB* cord blood, *CCNU* lomustine, *Cy* cyclophosphamide, *HID* haploidentical donor, *MD* matched donor, *MFD* matched family donor, *MMD* mismatched donor, *MSD* matched sibling donor, *MMUD* mismatched unrelated donor, *MUD* matched unrelated donor, *OS* overall survival, *PID* primary immunodeficiency, *SCID* severe combined immunodeficiency, *TBI* total body irradiation, *UD* unrelated donor, *WAS* Wiskott-Aldrich syndrome

RTC Regimens in PID {#Sec4}
===================

The use of reduced toxicity conditioning regimens are now generally preferred for patients with PID as there is no malignant disease to eradicate, stable mixed chimerism achieves cure for many diseases, and many patients enter HCT with chronic infections and end-organ comorbidities. Additionally, many patients are infants at the time of transplant and may be more susceptible to toxicity \[[@CR10]\]. Less toxic regimens may reduce early and late adverse effects, particularly infertility \[[@CR4]•\]. There are several reduced toxicity regimens that have been utilized by investigators in PID (Table [2](#Tab2){ref-type="table"}) \[[@CR14]•, [@CR49], [@CR50]\].Table 2Outcome of HCT in PID according to reduced toxicity conditioning regimensAuthor, yearYear of HCTNo of patients/diagnosisMedian age at HCT (range), yearsDonor and stem cell sourceConditioning regimen and GvHD prophylaxisMedian day of N engraftmentVOD, *n*aGvHD %cGvHD %OS %ES %Graft failure %Second procedure, *n*Latest donor chimerism/remarksFludarabine and treosulfan  Slatter, 2018 \[[@CR11]\]2006--201316039 SCID20 WAS17 CGD18 HLH66 Other PID:1.36(0.1--18.3)29 MSD/MFD73 MUD54MMUD4 HID49 marrow70 PBSC41 CBFlu 150 mg/m^2^ + Treo 42 g/m^2^ (36g/m^2^ if \< 1 year; 30 g/m^2^ for SCID) + alemtuzumab 0.3 to 1.0 mg/kgGvHD prophylaxis: CSA/MMFNA0I--IV: 46III--IV: 9152-year OS: 885-year OS: 782-year ES: 885-year ES: 7834 s HCT for graft loss or poor immune reconstitution5 unconditioned boost3 DLIPBSC was associated with better donor myeloid chimerism without an increased risk of GvHD  Morillo-Gutierrez, 2016 \[[@CR12]\]2006--201570 CGD8.9 (IQR 3.8--19.3)13 MSD/MFD44MUD12 MMUD1 HID36 marrow32 PBSC1 TCR ∝β/CD19 depleted PBSC1 CB46 Flu150mg/m^2^ + Treo 42 g/m^2^ (36g/m^2^ if \< 1 year)Alemtuzumab (*n* = 39) or ATG (*n* = 18) or no serotherapy (*n* = 13)15 Flu + Treo + TT + alemtuzumab or ATG9 other Treo-based conditioning regimenGvHD prophylaxis:CSA ± MMF or MTX17 (IQR 15--35)0I--II: 39III--IV: 121391.481.4128 (2 unconditioned boost; 3 DLI; 5 conditioned 2nd HCT \[2 had DLI\])Myeloid ≥ 95%: 80% surviving patients  Slatter, 2015 \[[@CR13]\]2005--2010316144 PID39 IMD70 H-globinopathy32 histiocytic disorders24 marrow failure2 autoimmune disease5 others\< 1 year, *n* = 951--12 years, *n* = 189\> 12 years, *n* = 3294 MSD/MFD29 MMRD39 MUD16 MMUD138 undefined UD167 marrow8 marrow + CB3 marrow + PBSC87 PBSC1 PBSC + CB50 CB106 Flu 150 mg/m^2^ + Treo 42 g/m^2^98 Cy 200 mg/kg + Treo 42 g/m^2^104 Flu 150 mg/m^2^ + Treo 42 g/m^2^ + TT 8 mg/kg8 Flu 150 mg/m^2^ + Treo 42 g/m^2^ + melphalanGvHD prophylaxis:284 CSA alone100 CSA + MMF101 CSA + MTXNA0I--IV: 38III--IV: 10NA83765.1NANA  Burroughs, 2014 \[[@CR14]\]2009--2013316 IPEX5 CGD2 other PID6 HLH6 BM failures6 RBC disorders10.7 (0.4--30.5)4 MSD27 MUD29 marrow2 PBSCFlu 150 mg/m^2^ + Treo 42 g/m^2^Serotherapy:22 ATGGvHD prophylaxis:Tacrolimus + MTX21 (range, 12--46)0II--IV: 62III--IV: 102190NA32 s HCT*ATG patients:*19 (86%) full or high level of mixed CD3 chimerism3 (14%) low-level mixed donor CD3 chimerism*No ATG patients:*6 full/high level of mixed CD3 chimerism2 low-level mixed donor CD3 chimerism1 graft failure  Dinur-Schejter, 2015 \[[@CR15]\]2009--201345 HCT in 44 patients12 SCID5 severe congenital neutropenia2 WAS2 CGD1 HLH10 PID5 thalassaemia5 osteopetrosis3 IMD4 others1.5 (0.1--15.1)19 MSD/MFD3 MMFD14 MUD9 unrelated CB19 Flu + Treo6 Cy + Treo20 Flu + Treo + TT(Treo 36 g/m^2^ for \< 1 year; 42 g/m^2^ for \> 1 year)Serotherapy:9 no serotherapy26 ATG8 Alemtuzumab1 OKT3Flu/Treo/TT: 18.4Flu/Treo: 25.3Cy/Treo: 19.51I--IV: 44.4III--IV: 2718.97155143 s HCT (one had a further 3rd HCT)Full: 31 (72%)Mixed: 6 (28%)  Lehmberg, 2014 \[[@CR16]\]2010--201219 HLH3.9 (0.2--22)1 MRD6 MUD9 MMUDHID 117 marrow1 PBSC1 CD34 selected PBSC for HID16 Flu150mg/m^2^ (3 Flu 160-180 mg/m^2^) + Treo 42 g/m^2^ (36g/m^2^ if \< 12 kg)Alemtuzumab 0.3 mg---1.0 mg/kg14 additional TT 10 mg/kg (7 mg/kg if \< 12 kg)GvHD prophylaxis:2 CSA alone7 CSA + MMF9 CSA + MTX1 Tacrolimus + MMF20 (range 11--62)1I--II: 21III--IV: 1 patient after DLINo100NA11 (*n* = 2)2 s HCT(1 1° graft failure after HID; 1 2° graft failure)6 DLIWB \> 95%: 10WB 75--95%: 2WB 20--74%: 4  Beier, 2013 \[[@CR17]\]2003--200953 non-malignant patients10 SCID4 CGD2 HLH2 WAS11 other PID3 osteopetrosis9 H-globinopathy9 BM failure1 IMD2 0thers4.8 (0.1--20.1)16 MSD/MFD1 MMFD1 MUD25 MUDI HID2 CB + HID36 marrow11 PBSC1 CB2 CB + PBSC2 NA15 Flu + Treo (1 additional radioimmunotherapy)32 Flu + Treo + TT5 Flu + Treo + melphalanSerotherapy4 None19 ATG3 ATG + OKT31 ATG + alemtuzumab16 alemtuzumab1 alemtuzumab + rituximab1 rituximab5 OKT3200I--IV: 32III--IV: 46 (*n* = 3)87NA4NAFull: 46 (87%)  Slatter, 2011 \[[@CR18]\]2006--20097026 SCID7 Omenn syndrome7 WAS4 HLH4 LAD4 CGD2 IPX16 other PID0.7 (0.1--14.6)21 MSD/MFD45 MUS4 HID40 Flu150mg/m^2^ + Treo 42 g/m^2^30 Flu150mg/m^2^ + Cy 200 mg/kg53 alemtuzumab 0.3 to 1.0 mg/kgNA2 in Cy groupI--IV: 26III--IV: 10681Flu: 85%Cy: 77%NA3 (*n* = 2_1 had both top-up and second conditioned HCT57% full donor chimerism43% stable mixed chimerismBusulfan ± fludarabine  Dvorak, 2019 \[[@CR19]\]2011--2017104 typical SCID6 leaky SCID5 mos (range, 2--108 mos)2 MUD2MMUD6 HIDMarrow for MUD/MMUDCD34 selected PBSC or HIDBu with target AUC 30 mg\*hr./L ATG or alemtuzumabFor patients with any T cells:Additional Flu 160 mg/m^2^For patients with NK cells:Additional TT 10 mg/kg2 had plerixafor 9 h prior to each dose of Bu16 (range, 14--23)0II--IV: 2 patients0100NA101 additional HCTMedian myeloid at one-year post HCT14% (range, 2--100%)6 had full T- and B cell reconstitution3 had no B cell recovery (2 had rituximab for autoimmunity post-HCT)3 had B cell autoimmunity  Güngör, 2015 \[[@CR20]\]2003--201556 CGD12.7 (IQR 6.8--17.3)21 MSD/MFD25 MUD10MMUD45 marrow11 PBSCFlu 150 mg/m^2^Bu with target AUC 45--65 mg\*hr./LxhSerotherapyATG for MFDAlemtuzumab for MUD19 (IQR 16--22)0III--IV: 47938953 s HCTMyeloid \> 90%: 52 (93%)  Jacobsohn, 2004 \[[@CR21]\]2000--2004136 PID4 H-globionopathy3 IMD5.2 (IQR, 0.6--11.1)4 MSD1MMFD6 MUD2 unrelated CB11 PBSCFlu 150 mg/m^2^Bu with target AUC 3800 to 4200umol x minATGGvHD prophylaxisCSA ± MMF18 (IQR, 14--25)0II--IV: 82584NA15(2 h-globinopathy)none72% full donor chimerismFludarabine and melphalan  Allen, 2018 \[[@CR22]\]2013--201534 HLH12 PID2.3(0.4--28)7 MSD1 MMRD25 MUD13 MMUDAll had marrowFlu 150 mg/m^2^Melp 140 mg/m^2^Alemtuzumab 1 mg/kgGvHD prophylaxisCSA and steroid130II--IV: 17.4III--IV: 10.926.718-month OS: 66.9%60.9% with second procedure39.1% without interventionPrimary: 4Secondary: 42 s HCT57% had full chimerism in all cell lines42% had stable mixed chimerism  Fox, 2018 \[[@CR23]\]2004--201429 PID24 \[[@CR11], [@CR12], [@CR16], [@CR18]--[@CR48]\]11 MFD13 MUD5 MMUDNon-CGDFlu 150 mg/m^2^Melp 140 mg/m^2^Alemtuzumab 100 mgCGDFlu 150 mg/m^2^Meph 10 mg/m^2^ or Bu 9.6 mg/kgAlemtuzumab or ATGGvHD prophylaxisCSA13 (IQR, 11--17)0I--II: 45III--IV: 3Limited: 34Extensive: 11-yr: 85.21-year: 85.7NoneNone85% full chimerism  Marsh, 2010 \[[@CR30]\]2003--200940 HLH1 (0.1--16)7 MFD33 MUD36 marrow2 PBSC2 CB26 RICFlu 150 mg/m^2^ (5mg/kg if \< 10 kg)Melp 140 mg/m^2^ (4.7 mg/kg if \< 10 kg)Alemtuzumab14 MACBu 14 mg/kgCy 200 mg/kg12 additional etoposide 30 mg/kgGvHD prophylaxisCSA or tacrolimus + steroid/MTXMAC: 14.5RIC: 10NAII-IIIMAC: 14RIC: 8(*p* = 0.317)MAC: 0RIC: 12% limitedMAC: 43%RIC 89%(*p* = 0.0036)NANone3 CD34+ boost14 DLIMAC: 18% mixedRIC: 65% mixedMixed chimerism in RIC was less in patients who received distal aleumtuzumab (29%) vs 79% in proximal alemtuzumab (*p* = 0.02)  Rao, 2005 \[[@CR49]\]1998--2001336 SCID27 non-SCID5.9 (0.19--18)22 MUD11 MMUDAll marrowFlu 150 mg/m^2^Melp 140 mg/m^2^Alemtuzumab 1 mg/kgCSA13 (range, 8--34)0II--IV: 9Limited: 0Extensive: 394%NANANA55% had full chimerism32% had high level mixed chimerism6.5% had low level mixed chimerism6.5% very low mixed chimerism  Amrolia, 2000 \[[@CR31]\]NA83 SCID1 XLP/HLH2 CID2 CD40 ligand def6.5 (range, 0.75--18)2 MSD6 MUDAll marrowFlu 150 mg/m^2^Melp 140 mg/m^2^ALG 10 mg/kgGvHD prophylaxisCSA and steroid13 (range, 9--17)0I: 50II--IV: 0limited cGvHD, *n* = 188NA1 patientNone4 had 100% donor chimerism3 had mixed chimerismFludarabine and low-dose TBI  Burroughs, 2010 \[[@CR36]\]NA2 IPEX0.75, 162 MUD1 marrow1 PBSCFlu 90 mg/m^2^TBI 4GyGvHD prophylaxisCSA and MMF16, 1702 had grade II1 severeBoth aliveBoth engraftedNoneNoneFull immune function and normal FOXP3 protein expression  Burroughs, 2007 \[[@CR35]\]1998--200614 PIDRange 0.5--308 MFD8 MUD8 marrow5 PBSC1 CBFlu 90 mg/m^2^ (*n* = 13)TBI 2Gy (*n* = 14)GvHD prophylaxisCSA and MMF15 (range 5--23)0II: 71III--IV: 7Extensive: 47626211 unconditioned PBSC for slipping myeloid chimerism1 conditioned HCT for persistent thrombocytopenia1 DLI for low donor CD4 and CD8 chimerism1 conditioned HCT for graft failure5 mixed chimerism8 full donor chimerismAntibody-based conditioning  Schulz, 2011 \[[@CR44]\]2003--200714 non-malignant4 SCID2 CGD2 Hyper IgM2 other PID4 H-globinopahty7.5 (range, 1--20)3 MFD1 MMFD8 MUD2 HID8 marrow4 PBSC2 TCD-PBSC^90^Y-labeled anti-CD66 antibody at Day −14Fludarabine 160 mg/m^2^Melphalan 70-140 mg/m^2^ATG for mismatched donor and unrelated donorNA0II: 36III--IV: 0limited, *n* = 2extended, *n* = 38881*n* = 119 had 100% chimerism2 had mixed chimerism  Straathof, 2009 \[[@CR24]\]1999--2002168 SCID1 MHC class II def.1 IPEX1 HLH1 DKC + SCID1 Ligase 4 def.1 CD40 ligand def.2 Other PIDs0.7 (range, 0.4 to 11.4)5 MSD9 MUD2 MMUDD40 marrow12 PBSC1 PBSC + marrow17 CBAnti-CD45 1.6 mg/kg (day − 5 to − 2)Flu 150 mg/m^2^Alemtuzumab 0.3 to 0.6 mg/kgGvHD prophylaxisCSA and MMF9.5 (range 1--15)0II--IV: 38III--IV: 1931819531 s HCTMedian myeloid: 100% (range, 41--100%)Median lymphocyte: 100% (range, 54--100%)*1°* primary, *2°* secondary, *aGvHD* acute graft-versus-host disease, *ALG* antilymphocyte globulin, *ATG* anti-thymocyte globulin, *AUC* area under curve, *BM* bone marrow, *BU* busulfan, *CB* cord blood, *CGD* chronic granulomatous disease, *cGvHD* chronic graft-versus-host disease, *CSA* ciclosporin, *def* deficiency, *DLI* donor lymphocyte infusion, *ES* engrafted survival, *Flu* fludarabine, *H-globinopathy* hemoglobinopathy, *HID* haploidentical donor, *HLH* hemophagocytic lymphohistiocytosis, *IMD* inherited metabolic disease, *IQR* interquartile range, *MMF* mycophenolate mofetil, *MMRD* mismatched related donor, *MMUD* mismatched unrelated donor, *MSD* matched sibling donor, *MUD* matched unrelated donor, *MTX* methotrexate, *N* neutrophil, *NA* not available, *OS* overall survival, *PID* primary immunodeficiency diseases, *SCID* severe combined immunodeficiencies, *Treo* treosulfan, *TT* thiotepa, *vs* versus, *WAS* Wiskott-Aldrich syndrome, *WB* whole blood

Fludarabine and Treosulfan {#Sec5}
--------------------------

Treosulfan (L-treitol-1,4-bis-methanesulfonate) is a prodrug and a water-soluble bifunctional alkylating agent which has been used for many years as treatment for various neoplasms, but more recently as part of conditioning for HSCT. In addition to myeloablative properties, it has marked immunosuppressive properties which contribute to the achievement of stable engraftment posttransplant. It causes relatively low organ toxicity compared to high-dose busulfan and cyclophosphamide leading to fewer complications such as veno-occlusive disease of the liver.

The first successful allogeneic transplant in a child using treosulfan was performed in 2000 and since then many reports have confirmed its efficacy and safety in both malignant and non-malignant disorders \[[@CR11]••, [@CR12]•, [@CR13], [@CR14]•, [@CR15]--[@CR18]\]. Slatter et al. first published results of 70 children with PID who received treosulfan in combination with either cyclophosphamide (*n* = 30) or fludarabine (*n* = 40) with an overall survival of 81% (median follow-up 19 months) equivalent in those aged less or greater than 1 year at time of transplant \[[@CR13]\]. Toxicity was low but worse after cyclophosphamide, and T cell chimerism was significantly better after fludarabine \[[@CR18]\]. Slatter et al. more recently reported 160 patients who had received conditioning with treosulfan and fludarabine achieving a probability of 2-year survival of 87.1% with a high level of complete or stable mixed chimerism in the diseased cell lineage, sufficient to cure disease \[[@CR11]••\]. There was a high survival rate in children transplanted under 1 year of age in whom toxicity can be a problem with conventional and other reduced intensity conditioning regimens \[[@CR24], [@CR25]\]. A 100-day survival of 94% demonstrated the low toxicity of this regimen making it suitable for patients with PID who often have infection and organ damage prior to HCT. In this series, a higher level of myeloid chimerism was found in recipients of PBSC compared to CB and BM, without an increased risk of grade III/IV acute or chronic graft-versus-host disease (GvHD). This highlights the importance of the whole transplant package including stem cell source and serotherapy when tailoring therapy \[[@CR26]\].

Excellent results were reported by Lehmberg et al. in 19 patients with hemophagocytic lymphohistiocytosis (HLH) following HCT with treosulfan, fludarabine, alemtuzumab, with or without thiotepa, all of whom survived with a median follow-up of 16 months \[[@CR16]\].

Haskologlu et al. reported 15 patients with PID who had a high risk of developing transplant-related toxicity due to previous lung and liver damages and were given treosulfan-based conditioning \[[@CR27]\]. At 32 months follow-up, the overall survival was 86.7% with excellent chimerism and low conditioning associated morbidity despite the high-risk population.

Mixed chimerism is sufficient to achieve cure in some non-malignant disorders, but the specific diagnosis and level of chimerism needed to achieve cure must be taken into account when balancing the need for increased myeloablation against short- and long-term toxicities from the conditioning regimen. The addition of thiotepa is common in order to increase the intensity of the regimen, but there are few reports of any comparison in outcomes comparing treosulfan and fludarabine with or without additional thiotepa. Yael Dinur-Schejter et al. reported 44 patients with non-malignant diseases: 19 received treosulfan with fludarabine 66.7% of whom achieved complete engraftment compared to 94.7% of 20 patients who received additional thiotepa, but this did not translate into any significant difference in overall or event free survival \[[@CR15]\].

Fludarabine and Busulfan {#Sec6}
------------------------

Traditionally, busulfan (Bu) was used in combination with cyclophosphamide (Cy) as the standard myeloablative conditioning regimen for HCT for both malignant and non-malignant disorders in both adult and pediatric patients. Cyclophosphamide is increasingly being substituted with fludarabine (Flu), a nucleoside analogue with immunosuppressive properties, to provide a less toxic but equally effective regimen \[[@CR19], [@CR21], [@CR28]\].

Harris et al. compared 1400 children who received Bu-Cy to 381 who received Bu-Flu. Busulfan doses were comparable between the 2 groups and the majority had pharmacokinetic monitoring. Eight hundred and three had non-malignant disorders including 195 with PID who received Bu-Cy and 86 who received Bu-Flu. Nine hundred and seventy-eight had malignant disorders. Children receiving Bu-Flu for non-malignant conditions experienced less toxicity than those receiving Bu-Cy, but survival was comparable. Children with malignancy had shorter postrelapse survival with Bu-Flu than Bu-Cy although transplant-related mortality and relapse were similar \[[@CR29]\].

The pharmacokinetics of busulfan have been studied extensively and the use of a lower target area under the curve (45--65 mg/L × h) combined with fludarabine has been pioneered by Tayfun Güngör and colleagues in Zurich. Particularly impressive results have been seen using this regimen for patients with chronic granulomatous disease (CGD). Fifty-six children and young adults with CGD were reported, many of whom had high-risk features such as intractable infections and autoinflammation. Twenty-one HLA-matched related-donor and 35 HLA-matched unrelated-donor transplants were done. The 2-year probability of overall survival was 96% (95% CI 86∙46--99∙09), and of EFS was 91% (79∙78--96∙17). Graft-failure occurred in 5% (three of 56) of patients. The cumulative incidence of acute GvHD of grade III--IV was 4% (two of 56) and of chronic GvHD was 7% (four of 56). Stable (≥ 90%) myeloid donor chimerism was documented in 52 (93%) surviving patients \[[@CR20]••\].

Dvorak et al. have recently reported the result of the use busulfan at a lower target area under the curve (30 mg/L × h) alone or in combination with fludarabine or thiotepa in 10 patients with severe combined immunodeficiency. All the patients survived, one patient required second HCT, and 3 had no B cell reconstitution \[[@CR19]\].

RIC in PID {#Sec7}
==========

Fludarabine and Melphalan {#Sec8}
-------------------------

Increasing recognition of the significant toxicities associated with conventional doses of busulfan and cyclophosphamide, particularly in very young infants and especially in those with pre-existing end organ damage, led to the adoption of immunosuppressive-based, rather than myelo-ablative-based regimens, with fludarabine and melphalan. The results, principally in those with significant preexisting comorbidities, were striking with significantly improved early survival \[[@CR22], [@CR23], [@CR30], [@CR31], [@CR49]\]. However, donor chimerism was not always optimal, and there was a high incidence of late viral reactivation, and late onset acute GvHD. Furthermore, toxicities in infants \< 1 year of age remained significant \[[@CR25]\]. Melphalan in particular has been associated with cardiac toxicities \[[@CR32]\]. Good results have been reported for patients with hemophagocytic lymphohistiocytosis \[[@CR33]\]. Patients with X-linked inhibitor of apoptosis protein (XIAP) deficiency, which is difficult to transplant, also have good outcomes reported using fludarabine and melphalan-based regimens \[[@CR34]\]. It has been used in adults with PID with good transplant survival \[[@CR23]\]

While the approach remains attractive in terms of reduced toxicities, concerns regarding late graft failure and high mortality in the \< 12-month-aged infants remain.

Minimal Intensity Conditioning for PID {#Sec9}
======================================

Fludarabine and Low-Dose TBI {#Sec10}
----------------------------

Burroughs et al. from the Seattle group have reported the transplant outcome of using fludarabine and low-dose TBI in 14 PID patients with significant preexisting organ dysfunction and infections. All received posttransplant GvHD prophylaxis with cyclosporin and mycophenolate mofetil but no serotherapy. Overall survival at 3 years was 62%, but there were high rates of acute (79%) and extensive chronic GvHD (47%) \[[@CR35]\]. One had graft failure and an additional three patients required a second procedure for decreasing chimerism. Of 10 evaluable patients, 8 had correction of immune deficiency with stable chimerism. However, the high rate of GvHD has limited the broader use of this conditioning regimen in children with PID \[[@CR35], [@CR36]\].

Antibody-Based {#Sec11}
--------------

While conditioning regimens have undoubtedly become less toxic, the ability to achieve donor chimerism without the use of chemotherapeutic agents, particularly in patients with non-malignant disease, is extremely attractive. Furthermore, some primary immunodeficiencies have significant toxicities associated with the administration of alkylating agents, due to the nature of the molecular defect, leading to serious long-term effects or early mortality \[[@CR37]--[@CR39]\]. A number of different strategies have been employed to minimize the exposure to chemotherapeutic agents by the use of antibodies to aid stem cell engraftment, with or without adjunct chemotherapy.

Anti-CD45 Antibodies {#Sec12}
--------------------

CD45 is selectively expressed on all leucocytes and hematopoietic progenitors but is absent on non-hematopoietic tissues. Straathoff and colleagues studied 16 patients with PID who were less than 1 year of age or had significant preexisting comorbidities and were felt not suitable for conventional reduced intensity conditioning \[[@CR24]\]. The conditioning regimen was comprised of alemtuzumab 0.2 mg/kg daily for 3 days for unrelated donors, or 0.1 mg/kg daily for 3 days for matched sibling donors on day − 8 to day − 6, clinical grade rat anti-CD45 (YTH24·5and54·12) 0.4 mg/kg on day − 5 to day − 2, fludarabine (30 mg/m^2^ daily for 5 days on day − 8 to day − 4) and cyclophosphamide (300 mg/m^2^ daily for 4 days on day − 7 to day − 4). Twelve patients were alive and well at the end of the study, one failed to engraft and was successfully re-transplanted, and 3 died---none of conditioning toxicity. Donor chimerism was variable but high level and sufficient to cure disease in the survivors.

Radioimmunotherapy {#Sec13}
------------------

Radioimmunotherapy is an attractive concept for conditioning of patients with PIDs as it exploits of the physical cytotoxic effect of radiation and reduces the toxicity to other organ systems by its internal application and the conjugation of radioisotopes to specific antibodies \[[@CR40]\]. Radioisotopes emitting α, β or γ-radiation of calculated intensity can be brought in direct proximity to the cells of interest. This enables malignant cells to be eradicated or benign hematopoietic cells to be depleted as part of conditioning before autologous or allogeneic HSCT. The method was developed to allow better and more specific control of malignant cells in the setting of HSCT without an increase in non-relapse mortality. Considerable clinical data was accumulated with conjugates of ^90^Yttrium or ^131^Iodine to anti-CD20 antibodies in the treatment of patients with refractory or recurrent B cell non-Hodgkin lymphoma (B-NHL). The drugs were used in combination with chemotherapy to prepare patients for autologous and allogeneic stem cell transplantation. This experience resulted in the approval of two drugs (Zevalin® and Bexxar®) by the FDA at the beginning of the century \[[@CR40]\].

The use of RIT for the treatment of leukemias or for myeloablation in non-malignant disease until present is limited to clinical studies. A conjugate of ^131^Iodine to anti-CD45-antibody was explored in the treatment of patients with AML and high-risk MDS, again a combination of RIT with conventional myeloablative or immunosuppressive drugs was used for conditioning before allogeneic HSCT \[[@CR41], [@CR42]\]. CD45 is expressed on most AML and ALL blasts as well as on virtually all developing and mature cells of normal hematopoiesis. Radiolabeled anti-CD45 antibody doses up to 43 Gy were administered to the bone marrow in combination with RIC and allogeneic transplantation with good tolerance and without additional toxicity in younger adult patients with AML and MDS \[[@CR43]\]. For children, limited published data exists for the use of RIT for pretransplant conditioning. A conjugate of ^90^Yttrium to an antibody targeting CD66 was used in combination with melphalan and fludarabine or TBI for the treatment of children with considerable comorbidities with malignant and non-malignant disease. ^90^Yttrium emits pure β-radiation with a maximum range of 11 mm and a half-life of 2.7 days \[[@CR44]\]. With these qualities, no isolation of the pediatric patients was necessary, but the dosimetry had to be performed with another isotope, emitting γ-radiation to be detected in a γ-camera. CD66 is abundantly present on mature myeloid cells but usually not expressed on malignant blasts. The therapeutic principle of RIT with this antibody in malignant disease therefore relies on the so-called cross-fire effect, which describes the indirect depletion of blasts by binding of the antibody to cells in close proximity \[[@CR40]\]. In order to avoid graft rejection in unrelated or mismatched grafts, recipients received serotherapy with ATG in this setting. Fifteen of 16 children with non-malignant disease survived the procedure, 13/15 with complete donor chimerism. The Kaplan-Meier estimation for disease-free survival at 24 months was 94%. This clearly documented feasibility of and reliable myeloablation by RIT in children and young adults with non-malignant disease.

Anti-CD117 Antibodies {#Sec14}
---------------------

The molecule CD117 (c-Kit receptor) is expressed on hematopoietic stem cells at all stages of development. Interactions with the ligand of CD117, stem cell factor, are crucial for hematopoietic stem cell survival, and this signaling pathway plays a critical role in the homing, adhesion, maintenance, and survival of hematopoietic stem cells in the hematopoietic niche. Preclinical studies demonstrated that using an antibody against CD117 to impede CD117-stem cell factor signaling selectively depleted hematopoietic stem cells with no effect on differentiated progenitor or mature cell lineages, and enabled engraftment of donor cells \[[@CR45]\]. A clinical trial is currently in progress using anti-CD117 antibody alone to treat patients with primary immunodeficiencies (AMG191 Conditioning/CD34 + CD90 Stem Cell Transplant Study for SCID Patients, [ClinicalTrials.gov](http://clinicaltrials.gov) Identifier: NCT02963064). The early results of this dose finding study show that some donor stem cell chimerism, leading to donor T and B lymphocyte chimerism can be achieved \[[@CR46]\]. These preliminary data are extremely exciting and potentially lead the way to a step change in approaches to conditioning in patients with PIDs.

Conditioning for Haploidentical Donor Transplant {#Sec15}
================================================

As the outcomes of HCT using newer T cell depletion methods have improved, there is an increasing number of haploidentical transplants performed for both SCID and non-SCID PID. Various non-myeloablative conditioning regimens have been used in T-deplete and T-replete haploidentical transplant (Table [3](#Tab3){ref-type="table"}) \[[@CR5]••, [@CR47], [@CR48], [@CR51]\]. The Great North Children's Hospital (GNCH) group in Newcastle has used fludarabine, treosulfan, ATG (Grafalon), and ritixumab for patients who received CD3 TCR ab/CD19 depleted peripheral blood stem cells. Patients with non-SCID PID received additional thiotepa. The overall survival was comparable with family and unrelated donor transplant using a similar conditioning regimen \[[@CR18], [@CR51]\]. Neven et al. reported the outcome of Bu-Flu in 22 patients with PID received haploidentical transplant using posttransplant cyclophosphamide. The overall survival and donor chimerism were good, but 48% had acute GvHD and 24.2% had chronic GvHD.Table 3Outcome of haploidentical donor transplant in PID using modern T lymphocyte depletion strategies and various conditioning regimensAuthor, yearYear of HCTNo of patients/diagnosisMedian age at HCT (range), yearsDonor and stem cell sourceConditioning regimen and GvHD prophylaxisMedian day of N engraftmentVOD %aGvHD %cGvHD %OS %ES %Graft failure %Second procedure, *n*Latest donor chimerism/remarksFludarabine and treosulfan  Neven, 2019 \[[@CR48]\]2014--201722 PID5 osteopetrosis21 first HCT6 s HCT1.5 (0.2--17)27 HIDAll marrow20 MAC with Bu-pk + Flu 160 mg/m^2^ (4 received additional Cy 28 mg/kg)Serotherapy: rituximab plus alemtuzumab/ATG7 had RIC (1 first HCT and 6 s HCT)GVHD prophylaxisCSAMMFPTCy 50 mg/kg on day 3 + 419 \[[@CR11]--[@CR13], [@CR15]--[@CR34]\]11II--IV: 48II: *n* = 10III: *n* = 224.277.777.7*n* = 2124 full chimerism1 mixed chimerism  Shah, 2018 \[[@CR5]\]2012--201625 PID3 for refractory GvHD1.75 (0.28--10.3)23 HID2 MMUDTCR ab/CD 19 depleted PBSCFlu 150 mg/m^2^Treo 36-42 mg/m^2^TT 10 mg/kg24 had serotherapy (ATG/alemtuzumab)6 had rituximab3 SCID: unconditionedGvHD prophylaxis: CSF/MMF25 \[[@CR10]--[@CR19], [@CR21], [@CR24]--[@CR28], [@CR49], [@CR50]\]0II--IV: 22None83.980.4*n* = 1176.1% full donor chimerism5 had high T cell but mixed myeloid chimerism (2 unconditioned)  Rastogi, 2017 \[[@CR47]\]2013--20168 PID4.9 (0.8--12)7 HID1 MUDUnmanipulated marrow/PBSC5 Flu 160 mg/m^2^ + Cy 29 mg/kg + TBI 2Gy (3 had additional TT) + ATG/alemtuzumab2 Flu 160 mg/m^2^ + Treo 42 mg/^2^1 Flu 160 mg/m^2^ + Bu 3.2 mg/kgGVHD prophylaxisTacrolimusMMFPTCy 50 mg/kg on Day 3 + 4Mean 17NAI--II: 3 patientsII--IV: none2 limited7575NoneNoneAll full donor chimerism  Balashov, 2015 \[[@CR51]\]2012--201437 PID5 SICD32 non-SCID PID2.6 (0.2--17)27 MUD10 MMRDTCR ab/CD 19 depleted PBSCFlu 150 mg/m^2^Treo 36-42 mg/m^2^8 had Melphalan 140 mg/m^2^ for high risk graft rejection14 had rituximab1 unconditionedSerotherapy35 ATG2 alemtuzumab16 (range 11--28)NAMax grade 2 in 7 patientsOnly one had grade IV (no conditioning)1 patient (unconditioned)96.767.727%HID: 36%MUD: 28%10NA*aGvHD* acute graft-versus-host disease, *BU* busulfan, *cGvHD* chronic graft-versus-host disease, *CSA* ciclosporin, *ES* engrafted survival, *Flu* fludarabine, *HID* haploidentical donor, *MAC* myeloablative conditioning, *MMF* mycophenolate mofetil, *MMUD* mismatched unrelated donor, *MSD* matched sibling donor, *MUD* matched unrelated donor, *N* neutrophil, *NA* not available, *OS* overall survival, *PID* primary immunodeficiency diseases, *RIC* reduced intensity conditioning, *SCID* severe combined immunodeficiencies, *Treo* treosulfan, *TT* thiotepa, *WAS* Wiskott-Aldrich syndrome

Pharmacokinetic Studies {#Sec16}
=======================

Although levels of busulfan have been measured for many years, to target the narrow myeloablative therapeutic window, minimize toxicity from supra-therapeutic levels and avoid sub-myelo-ablation and rejection, it is only recently that the importance of pharmacokinetic monitoring of other agents of the conditioning cocktail has been appreciated.

Fludarabine Pharmacokinetics {#Sec17}
----------------------------

Ivaturi et al. prospectively studied the pharmacokinetics and pharmacodynamics of 133 children undergoing HCT for a variety of disorders with a variety of conditioning regimens but all included fludarabine. Young age and renal impairment were found to lead to an increased exposure. In the setting of malignancy, disease-free survival (DFS) was highest 1 year after HCT in subjects achieving a systemic fludarabine plasma (f-ara-a) cumulative area under the curve (cAUC) greater than 15 mg\*hour/L compared to patients with a cAUC less than 15 mg\*hour/L (82.6% versus 52.8%, *p* = 0.04) \[[@CR52]\]. Further development of model-based dosing may minimize toxicity and maximize efficacy, resulting in superior outcomes for malignant and non-malignant patients.

Treosulfan Pharmacokinetics {#Sec18}
---------------------------

Relatively high variability of treosulfan pharmacokinetics in pediatric patients may raise the need for implementing therapeutic drug monitoring and individual dose adjustment in this group. Vander Stoep et al. and Mohanan et al. recently published the first results of a relationship between the exposure of treosulfan and early toxicity, as well as clinical outcome, in children undergoing conditioning prior to HSCT. In the former study, patients with an AUC \> 1650 mg h/L demonstrated a statistically higher incidence of mucosal and skin toxicity than those with an AUC 1350 mg h/L (odds ratio 4.4 and 4.5, respectively). The odds of developing hepato- and neurotoxicity were also higher in the former group, but the difference did not reach statistical significance. No association was found between treosulfan exposure and early clinical outcomes, i.e., engraftment, donor chimerism, acute graft-versus-host disease, treatment-related mortality, and overall survival. PK parameters were shown to be age-dependent, with higher AUC values in younger children (\< 1 year old) and corresponding lower treosulfan clearance. A challenge in therapeutic monitoring of treosulfan within conditioning prior to HCT is a very brief course of treatment, consisting of three doses administered on 3 consecutive days. This allows personalization of only the second and third dose of the prodrug unless a test dose is applied prior to starting the actual regimen.

Since pharmacokinetic studies of treosulfan began, it has been assumed that plasma (serum) concentrations of the prodrug are a good representation of the alkylating activity of its epoxy transformers. However, for years, a correlation between treosulfan concentrations in plasma and levels of specific DNA adducts in tissues, for example the bone marrow, or clinical effects, have not been investigated. Therapeutic drug monitoring of not only prodrug but also its active epoxide might be needed. In addition blood pH, body temperature, and intravenous fluid delivery may influence glomerular filtration, tubular reabsorption, and nonenzymatic epoxy transformation of the prodrug \[[@CR53]\].

Serotherapy Levels {#Sec19}
------------------

It is now well recognized that type of serotherapy, dose and timing in relation to the transplant all have an impact on outcome of transplant in terms of occurrence of GVHD, immune reconstitution importantly in terms of viral reactivation, clearance of infection, and chimerism. Marsh RA et al. collected data from 105 patients to examine the influence of peritransplant alemtuzumab levels on acute GVHD, mixed chimerism, and lymphocyte recovery. Significantly higher levels of aGVHD but higher levels of donor chimerism, lymphocyte counts at D+30 and T cell counts at D+100 were associated with lower alemtuzumab levels at day 0 \[[@CR54]\].

In a recent report, the clearance of the active components of the 2 widely used types of ATG (Fresenius/Grafalon and Genzyme) was studied in 38 children with malignant hematological disorders. They found that ATG Fresenius was cleared rapidly and uniformly from the circulation whether they received 60 mg/kg or 45 mg/kg, but there were significant differences in patients who received a high dose of ATG Genzyme (10 mg/kg) who had significantly slower reconstitution for CD3, CD4, and CD8 T cells compared to patients who received a low dose of ATG Genzyme (6--8 mg/kg) or ATG Fresenius \[[@CR55]\].

Stem Cell Source in Non-MAC Conditioning {#Sec20}
========================================

Historically bone marrow has been the preferred stem cell source for HCT in children due to concerns that peripheral blood stem cell products led to an increased risk of GVHD. In Slatter et al.'s report of 160 PID patients who received uniform conditioning with treosulfan and fludarabine, a higher level of myeloid chimerism was found in recipients of PBSC compared to CB and BM, without an increased risk of grade III/IV acute or chronic GvHD \[[@CR26]\]. This is an important finding particularly for patients with diseases where a high level of chimerism is required to achieve complete cure.

Conclusions {#Sec21}
===========

The use of RTC and RIC has been a major paradigm shift in HCT for PID and may have contributed to improved survival through a reduction in early post-HSCT toxicities. Almost certainly, long-term toxicities will be reduced, although further data are required to confirm this. However, the use of antibody-based conditioning regimens is likely to transform the field in the future. The drive for this has been that PID can be completely cured by HCT, and as malignancy is rarely a feature of the disease, toxicity from the curative procedure should be minimized. More recently, newborn screening for severe combined immunodeficiencies has meant that these patients are now being identified by 2--3 weeks of age \[[@CR56]\]. Rapid transplantation is preferred, as survival and neurological outcome results are best in patients with no preexisting infection \[[@CR57], [@CR58]\]. As gene therapy approaches become mainstream treatment, then a non-toxic conditioning approach followed by an autologous gene-corrected stem cell procedure should almost eliminate short- and long-term treatment-related morbidities for patients with SCID \[[@CR59], [@CR60]\]. These conditioning approaches will have to be modified for combined immunodeficiencies and gain-of-function diseases where high-level or complete donor chimerism is required to abolish disease manifestations \[[@CR61]--[@CR64]\]. However, combinations of antibody-based regimens and pharmacokinetically targeted reduced low-toxicity agents may help resolve these issues. The future for patients with PID looks extremely encouraging.
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